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Abstract
One of the least-appreciated advances in pediatric rheumatology over the past 25 years has been
the delineation of the many ways in which children with rheumatic disease differ from adults with
the same illnesses. Furthermore, we are now learning that paradigms that are useful in evaluating
adults with musculoskeletal complaints have limited utility in children. Nowhere is that more true
than in the use of commonly used laboratory tests, particularly antinuclear antibody (ANA) and
rheumatoid factor (RF) assays. This short review will provide the practitioner with the evidence
base that supports a more limited use of ANA and RF testing in children.
Commentary
You've probably heard this dozens of times before, "This
might be a collagen vascular disease. Order an ANA and a
rheumatoid factor." It's common on adult wards, but it's
used with disturbing frequency on pediatric wards as well.
One of the least appreciated advances in pediatric rheu-
matology over the past 20 years has been the realization
that models used to evaluate adults with musculoskeletal
complaints do not serve children well [1]. Thus, it is per-
haps no surprise that children with even the most com-
mon form of juvenile idiopathic arthritis (JIA- the
currently accepted designation for the forms of chronic
arthritis that include what was previously termed juvenile
rheumatoid arthritis, JRA) are routinely referred to other
specialists before they see a pediatric rheumatologist [2],
at the same time that pediatric rheumatology services are
overwhelmed by referrals of children who do not have
rheumatic disease [3,4]. This pattern of referral almost
assuredly reflects, in part, the fact that joint pain is the
most common reason for referrals to pediatric rheumatol-
ogy clinics and the belief (based on adult models) that
joint pain is a symptom of chronic arthritis in children.
Work by McGhee and colleagues has shown unequivo-
cally, however, that it is not [5]. In that same study,
McGhee and colleagues reported that the second most
common reason for referral for pediatric rheumatology
consultation was "abnormal laboratory tests," most com-
monly ANA or rheumatoid factor assays. However, a
growing body of evidence accumulated over more than
twenty years has shown that these tests have limited or no
utility in the primary care settings where they are most
commonly used.
This short report will summarize some of the evidence
base that supports a more limited use of ANA and rheu-
matoid factor tests by primary care physicians evaluating
children for musculoskeletal complaints and/or suspected
rheumatic disease. It is intended as a review for primary
care physicians who wish to better understand how to use
and interpret these two commonly-ordered tests.
Rheumatoid factor (RF) tests remain a standard assay for
screening adult patients with musculoskeletal complaints
and, depending on the population studied, may be posi-
tive in as many as 85% of adults with rheumatoid arthritis
and fewer than 10% of healthy adult individuals [6]. This
test, now performed using several different methods,
detects IgM antibodies directed against the Fc portion of
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leagues [7] demonstrated that: [1] most children with pos-
itive RF tests don't have JRA/JIA; [2] most children with
JRA/JIA don't have positive RF tests; [3] children with JRA/
JIA who did have positive RF tests could be easily identi-
fied on the basis of the history and physical examination;
the test did nothing to establish the diagnosis. McGhee
and colleagues [5] corroborated this same finding, as
shown in Table 1. In that study, 16 children were referred
for evaluation of positive rheumatoid factor tests, three of
whom (19%) had JRA/JIA. Furthermore, as was reported
in the Eichenfield paper, the test added nothing to the his-
tory and physical examination, which would have estab-
lished the diagnosis even if the RF test had been negative.
Although the prevalence rate of RF-positive JRA/JIA is
higher in certain populations (e.g., American Indians [8]),
the diagnostic utility of this test is likely to be limited even
in high-prevalence populations, owing to the fact that: [1]
the prevalence of a positive test in healthy children from
the same populations is unknown; and [2] the exuberant
nature of the pathologic process in RF-positive children
allows the diagnosis to be made on the basis of the history
and physical alone, as demonstrated by both the McGhee
and Eichenfield groups. Indeed, Eichenfield and col-
leagues concluded that, "Testing for rheumatoid factor is
a poor screening procedure for juvenile rheumatoid
arthritis in the general situations in which it is more likely
to be requested..." [7]. Given that McGhee and colleagues
have corroborated the findings from the 1986 study, it
seems just as reasonable to state categorically that there is
never a reason to request a rheumatoid factor assay as a diag-
nostic test on a child. Pediatric rheumatologists will, how-
ever, continue to use rheumatoid factor testing as a
prognostic biomarker until better indicators of prognosis
emerge.
Antinuclear antibody (ANA) assays have the opposite
shortcoming of RF assays: they are commonly positive in
healthy children [9,10]) and the presence of ANA seems
to carry no increase in risk for eventually developing rheu-
matic disease [11]. Furthermore, McGhee and colleagues
[12] demonstrated that the titers of ANA seen in children
with diverse rheumatic diseases such as JRA/JIA, ankylos-
ing spondylitis, and dermatomyositis, so completely over-
lap those of healthy children as to make a positive test
useless in distinguishing a healthy child from one with
any of these diseases. Indeed, ANA tests showed diagnos-
tic utility only in identifying children with systemic lupus
erythematosus (SLE), where titers of ≥ 1:1,080 were com-
mon. However, even in children with SLE, there remained
considerable overlap in their ANA titers (1:360–1:640)
with those of otherwise healthy children.
The limits of ANA in evaluating children with suspected
JRA/JIA was corroborated in the earlier McGhee study [5],
as shown in Table 1. In that study, 90 children were
referred to a university-based pediatric rheumatology
service because of the results of ANA testing. Only 14 of
these children (16%) had JRA/JIA, and, as was seen with
rheumatoid factor testing, the ANA test did nothing to
support the diagnosis; that is, the diagnosis was already
apparent from the history and physical examination and
could have been made even if the test were negative. Based
on these data, it is reasonable to recommend that ANA be
used as a screening test in children only to answer one
diagnostic question: Does this child have systemic lupus? It
would be reasonable to propose, therefore, that a request
for ANA testing in a child be accompanied by requests for
a complete blood count and differential, urinalysis, and
serum C3 and C4 levels, all of which have a high likeli-
hood of being abnormal in childhood-onset systemic
lupus [13]. Not surprisingly, given the demographics of
systemic lupus, the positive predictive value of an ANA
test will be higher in adolescents (where the prevalence of
systemic lupus is higher) and lower in pre-pubertal chil-
dren, where systemic lupus is rare. Indeed, we feel confi-
dent in telling the parent of a child 10 years of age or
younger with an ANA test of ≤ 1:160 that, "The ANA test
was negative."
It should be evident from the foregoing discussion that
autoantibody testing has a much more limited utility in
the evaluation of children with musculoskeletal com-
plaints or suspected rheumatic disease than it does in
adults. This is not to say that the laboratory is not helpful.
A complete blood count and differential may, for exam-
ple, provide the diagnosis in a child with severe muscu-
loskeletal pain and refusal to walk, as musculoskeletal
pain, and even frank arthritis, are common presentations
of children with leukemia [14,15]. Similarly, in a child
with an erythematous, hyperkeratotic rash across her MCP
Table 1: Sensitivity of commonly used laboratory tests for diagnosing chronic arthritis in children#
Test cited as reason for referral Number Referred JRA/JIA Other
IgM-RF 16 3 (19%)* 13 (81%)
ANA 90 14 (16%) 76 (84%)
# – Summary of data from McGhee et al, ref. [5]Page 2 of 3
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and PIP joints (Gotron's papules), serum levels of CPK
and/or aldolase are very likely to reveal that the underly-
ing diagnosis is dermatomyositis [16].
The reader will note that, in each of the above examples,
the utility of the laboratory derives from the ability of the
clinician to formulate a differential diagnosis based on the
history and physical examination. Having a mental cate-
gory called "rheumatic disease" is not particularly helpful
in assessing children, as the different rheumatic diseases
display a broad spectrum of presentations, affect children
of different ages, and are characterized by physical find-
ings that show only limited overlap between the different
disease entities. This means, therefore, that the practi-
tioner needs to be familiar with the distinctive clinical pres-
entations of rheumatic disease in children, including the
typical signs and symptoms, age range of the affected chil-
dren, and diseases that mimic those under primary con-
sideration.
It is reasonable for clinicians to desire a simple "test" that
will allow them to consider or exclude "rheumatic dis-
ease" as a broad category in children. Unfortunately, such
a test doesn't exist, any more than there's a "test" that
excludes metabolic disease (aminoacidopathies present
with a very different clinical picture from that of disorders
of glucose metabolism) or endocrine disease (children
with defects in steroid synthesis present at different ages
and with different symptoms compared with children
with type 1 diabetes). There is no reason to believe that
such a test will ever emerge. We are therefore left with
what good primary care physicians have always relied on:
a good history, focused physical examination, and broad
knowledge base. After all, children aren't just adults.
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